Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis

Document Type

Journal Article

Publication Date

11-8-2025

Journal

Clinical and experimental dermatology

DOI

10.1093/ced/llaf490

Abstract

BACKGROUND: Lebrikizumab, a novel monoclonal antibody targeting interleukin-13, demonstrated durable and deep response on skin and itch in patients treated for 104 weeks in recent phase 3 trials (ADvocate1, NCT04146363; ADvocate2, NCT04178967; ADjoin, NCT04392154). OBJECTIVE: This analysis assessed stability of response through 2 years of continuous lebrikizumab treatment in Week 16 responders from ADvocate1 and ADvocate2 who continued the same treatment (lebrikizumab every 4 weeks [Q4W], N=99; lebrikizumab every 2 weeks [Q2W], N=82) in long-term extension study ADjoin. METHODS: Week 16 response was defined as Investigator's Global Assessment 0/1 with ≥2-point improvement from baseline or a ≥75% reduction in Eczema Area and Severity Index (EASI-75) without rescue medication. Stability was measured for EASI-75, EASI-90, and Pruritus Numeric Rating Scale (NRS) ≥3-point and ≥4-point improvement from baseline among Week 16 responders who had achieved the specified endpoint at Week 16. Stability was defined as maintenance of response for ≥80% of attended study visits from Weeks 16 through 104 (ADjoin Week 52). Observed data were analyzed regardless of rescue medication or discontinuation from treatment. RESULTS: With 104 weeks of continuous lebrikizumab treatment, 96.0% and 81.0% of Week 16 responders receiving lebrikizumab Q4W (91.5% and 79.2% for Q2W) showed stable EASI-75 and EASI-90 responses, respectively. Similarly, 93.8% and 87.9% of responders receiving lebrikizumab Q4W (88.7% and 87.2% for Q2W) showed stable responses for Pruritus NRS ≥3-point and ≥4-point improvement, respectively. CONCLUSIONS: A majority of lebrikizumab Week 16 responders maintained stable efficacy in measures of skin and itch during 2 years of treatment.

Department

Dermatology

Link to Full Text

Share

COinS